CytomX Therapeutics, Inc. (CTMX) has announced positive interim results from its ongoing Phase 1 study of CX-2051, a masked, conditionally activated EpCAM-targeting antibody-drug conjugate or ADC, in patients with advanced, late-line colorectal cancer or CRC.
In parallel, the company also disclosed the pricing of a $100 million underwritten public offering of common stock to support continued research and development.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com